Comparison of Transabdominal Preperitoneal and Totally Extraperitoneal Repair in Laparoscopic Inguinal Hernia: A Randomized, Clinical Trial on Postoperative Complications, Pain, and Functional Recovery.

J Laparoendosc Adv Surg Tech AMay 9, 2026 (epub)
Clinical ResearchGeneral Surgery

Amin Khayreddine Ghouali, Fouad Benamara, Loubna Bouhmama et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized clinical trial compared transabdominal preperitoneal (TAPP) and totally extraperitoneal (TEP) techniques for laparoscopic inguinal hernia repair in 144 adult male patients. The study found that 30-day postoperative complications were significantly more frequent after TAPP (19.4%) compared to TEP (6.9%, P = .024), indicating TEP may be the safer option in the short term.

Key findings

  • 30-day postoperative complications were 19.4% for TAPP vs 6.9% for TEP (P = .024).
  • Chronic pain at 3 months was 5.6% after TAPP and 1.4% after TEP (P = .181).
  • Recurrence rate was 2.8% in both groups after a median follow-up of 26 months.

Why it matters

Understanding the differences in postoperative outcomes between TAPP and TEP techniques can guide surgeons in selecting the appropriate method for inguinal hernia repair, potentially improving patient safety and recovery.

Source

PubMed · PMID 42104783

Published in J Laparoendosc Adv Surg Tech A. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.